NEW YORK (GenomeWeb News) – Austrian biomarker firm Biocrates and Canadian firm Chenomx have signed a co-marketing pact, under which the firms will combine their technologies to generate metabolic profiling tools for monitoring the effects of disease, nutrition, toxins, environment, or drugs on an organism.
Biocrates has developed a mass spectrometry-based platform, while Chenomx uses a unique methodology based on nuclear magnetic resonance spectroscopy to analyze biological samples. The firms said that by co-marketing their technologies they will be able to offer complementary metabolomic analyses, service a large common customer base, and jointly promote the use of each other's services.
"The two methods produce complementary data sets with very little overlap in results," Chenomx CEO Neil Taylor said in a statement. "Both tests can be run on the same samples thus offering a more comprehensive profile."
Biocrates has already brought to market a kit for metabolomics, which it will now evaluate and optimize on Chenomx's instrumentation and software.
Further terms of the alliance were not disclosed.